Sign In
Buy RAPT
$58.02
+0 (+0%)
At Close: Jun 01, 2026
SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing
RAPT Therapeutics to Participate in Upcoming Investor Conferences
04:30pm, Friday, 07'th Mar 2025
SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
08:00am, Thursday, 06'th Mar 2025
SOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”) is a clinical-stage immunology-based biopharmaceutical company
All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy
01:01pm, Monday, 10'th Feb 2025
Rapt Therapeutics (RAPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08:00am, Thursday, 09'th Jan 2025
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing a
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors
08:00am, Monday, 06'th Jan 2025
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing a
RAPT Therapeutics Announces $150 Million Private Placement
07:10am, Monday, 23'rd Dec 2024
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co
Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury
10:34am, Monday, 11'th Nov 2024
On Monday, Rapt Therapeutics, Inc. RAPT stock is trading lower after the company announced it was terminating its zelnecirnon (RPT193) program.
Down -15.94% in 4 Weeks, Here's Why Rapt Therapeutics (RAPT) Looks Ripe for a Turnaround
10:36am, Friday, 14'th Jun 2024
Rapt Therapeutics (RAPT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings e
Rapt Therapeutics (RAPT) Loses -47.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Wednesday, 29'th May 2024
Rapt Therapeutics (RAPT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings e
RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity
04:35am, Monday, 20'th May 2024
RAPT Therapeutics' lead candidate, zelnecirnon, is in phase 2 for atopic dermatitis and asthma with very promising ph1b results in atopic dermatitis and potential expansion in multiple indications. Li
Here's Why Rapt Therapeutics (RAPT) is Poised for a Turnaround After Losing -52.88% in 4 Weeks
10:36am, Monday, 13'th May 2024
The heavy selling pressure might have exhausted for Rapt Therapeutics (RAPT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street a
RAPT Therapeutics Reports First Quarter 2024 Financial Results
08:00am, Thursday, 09'th May 2024
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and com
- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status - Confirmed ORR of 17.4% in subset of patients with PD-L1+ disease - Confirmed ORR of 22.2% in subs
3 Biotech Stocks to Dump Before They Go to Zero
06:31am, Tuesday, 09'th Apr 2024
It is not a bad idea to hunt for biotech stocks to sell. Such stocks have earned a bad reputation among investors, and for good reason.
